Cargando…
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133930/ https://www.ncbi.nlm.nih.gov/pubmed/27869767 http://dx.doi.org/10.3390/ijms17111935 |
_version_ | 1782471370934845440 |
---|---|
author | Samalin, Ludovic Garnier, Marion Auclair, Candy Llorca, Pierre-Michel |
author_facet | Samalin, Ludovic Garnier, Marion Auclair, Candy Llorca, Pierre-Michel |
author_sort | Samalin, Ludovic |
collection | PubMed |
description | The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians’ decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia. |
format | Online Article Text |
id | pubmed-5133930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51339302016-12-12 Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics Samalin, Ludovic Garnier, Marion Auclair, Candy Llorca, Pierre-Michel Int J Mol Sci Article The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians’ decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia. MDPI 2016-11-19 /pmc/articles/PMC5133930/ /pubmed/27869767 http://dx.doi.org/10.3390/ijms17111935 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Samalin, Ludovic Garnier, Marion Auclair, Candy Llorca, Pierre-Michel Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics |
title | Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics |
title_full | Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics |
title_fullStr | Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics |
title_full_unstemmed | Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics |
title_short | Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics |
title_sort | clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133930/ https://www.ncbi.nlm.nih.gov/pubmed/27869767 http://dx.doi.org/10.3390/ijms17111935 |
work_keys_str_mv | AT samalinludovic clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics AT garniermarion clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics AT auclaircandy clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics AT llorcapierremichel clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics |